Coldstream Capital Management Inc. Purchases 60 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Coldstream Capital Management Inc. lifted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNFree Report) by 4.8% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 1,309 shares of the biopharmaceutical company’s stock after purchasing an additional 60 shares during the period. Coldstream Capital Management Inc.’s holdings in Regeneron Pharmaceuticals were worth $1,359,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. International Assets Investment Management LLC boosted its holdings in Regeneron Pharmaceuticals by 86,013.3% in the third quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock valued at $926,078,000 after acquiring an additional 879,916 shares in the last quarter. Worldquant Millennium Advisors LLC bought a new stake in Regeneron Pharmaceuticals in the third quarter valued at $127,489,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its holdings in Regeneron Pharmaceuticals by 23.8% in the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 500,274 shares of the biopharmaceutical company’s stock valued at $525,804,000 after acquiring an additional 96,266 shares in the last quarter. TD Asset Management Inc boosted its holdings in Regeneron Pharmaceuticals by 30.4% in the second quarter. TD Asset Management Inc now owns 351,545 shares of the biopharmaceutical company’s stock valued at $369,484,000 after acquiring an additional 82,034 shares in the last quarter. Finally, Icon Wealth Advisors LLC boosted its holdings in Regeneron Pharmaceuticals by 18,342.0% in the third quarter. Icon Wealth Advisors LLC now owns 75,981 shares of the biopharmaceutical company’s stock valued at $79,874,000 after acquiring an additional 75,569 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.

Wall Street Analysts Forecast Growth

REGN has been the topic of several recent analyst reports. Wolfe Research initiated coverage on shares of Regeneron Pharmaceuticals in a report on Friday, November 15th. They issued an “outperform” rating and a $1,150.00 price target on the stock. BMO Capital Markets cut their price target on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating on the stock in a report on Friday, November 1st. Citigroup initiated coverage on Regeneron Pharmaceuticals in a research report on Thursday, November 14th. They set a “neutral” rating and a $895.00 price objective for the company. Oppenheimer lowered their price objective on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating for the company in a research report on Wednesday, November 6th. Finally, Piper Sandler lowered their price objective on Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. One investment analyst has rated the stock with a sell rating, four have given a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $1,099.90.

View Our Latest Analysis on Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Price Performance

NASDAQ REGN opened at $773.00 on Thursday. Regeneron Pharmaceuticals, Inc. has a one year low of $735.95 and a one year high of $1,211.20. The stock has a 50-day moving average of $866.22 and a 200 day moving average of $1,009.07. The company has a market capitalization of $84.94 billion, a price-to-earnings ratio of 19.15, a PEG ratio of 3.00 and a beta of 0.08. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28.

Regeneron Pharmaceuticals Company Profile

(Free Report)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Featured Articles

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNFree Report).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.